8G72

SARS-CoV-2 spike/Nb2 complex with 1 RBD up (local refinement at 5.6 A)

Summary for 8G72

• Entry DOI: 10.2210/pdb8g72/pdb
• EMDB information: 29792 29793 29794 29795 29796 29797 29798 29799 29802 29803 29804 29805 29806
• Descriptor: Nanosota-2, Spike glycoprotein (2 entities in total)
• Functional Keywords: sars-cov-2, viral protein-immune system complex, nanobody, viral protein/immune system
• Biological source: Vicugna pacos (alpaca); More
• Total number of polymer chains: 2
• Total formula weight: 153640.49

Authors

Ye, G.,Bu, F.,Liu, B.,Li, F. (deposition date: 2023-02-16, release date: 2024-01-24, Last modification date: 2024-10-16)

Primary citation

Ye, G.,Pan, R.,Bu, F.,Zheng, J.,Mendoza, A.,Wen, W.,Du, L.,Spiller, B.,Wadzinski, B.E.,Liu, B.,Perlman, S.,Li, F.
Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
J.Virol., 97:e0144823-e0144823, 2023

PubMed Abstract: The COVID-19 pandemic exposed limitations of conventional antibodies as therapeutics, including high cost, limited potency, ineffectiveness against new viral variants, and primary reliance on injection-only delivery. Nanobodies are single-domain antibodies with therapeutic potentials. We discovered three anti-SARS-CoV-2 nanobodies, named Nanosota-2, -3, and -4, from an immunized alpaca. Nanosota-2 is super potent against prototypic SARS-CoV-2, Nanosota-3 is highly potent against the omicron variant, and Nanosota-4 is effective against both SARS-CoV-1 and SARS-CoV-2. In addition to their super potency and combined broad antiviral spectrum, these nanobodies are cost-effective, can be easily adapted to new viral variants through phage display, and can potentially be administered as inhalers. The Nanosota series are powerful therapeutic candidates to combat circulating SARS-CoV-2 and prepare for possible future coronavirus pandemics.

PubMed: 37855638
DOI: 10.1128/jvi.01448-23

Experimental method

ELECTRON MICROSCOPY (5.6 Å)